An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab Versus Extreme Study Revgimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) As First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Project: Research

StatusActive
Effective start/end date12/02/1911/02/24